AJ201 is a first-in-class pleiotropic small molecule under development by AnnJi for the treatment of Kennedy’s disease, a rare neurological disorder. Patient enrollment of a Phase 2a trial for AJ201 will be initiated in the US by the end of 2022.

Dr. Tsung-Pin (Andrew) Pai presented a scientific poster in “2022 International Conference of Big Data and Neurological Rare Diseases and Annual Meeting of Society for Neurological Rare Disorders-Taiwan” titled “JM17 for Treatment of Spinal-bulbar Muscular Atrophy and Neurodegenerative Disorders”, in which pharmacological activities of JM17, the active pharmaceutical ingredient (API) of AJ201, were reported, including anti-oxidation and anti-inflammation, as well as protein quality control. JM17 showed promising potential to treat neurological disorders associated with oxidative stress and inflammation.

AnnJi is a proud sponsor¹ of “2022 International Conference of Big Data and Neurological Rare Diseases and Annual Meeting of Society for Neurological Rare Disorders-Taiwan” and is committed to the development of innovative therapy for neurodegenerative diseases and close collaboration with physicians and researchers in neurological rare disease field.

1 https://sites.google.com/snerdtaiwan.org/2022-icbnrdsnerd-t-eng/sponsor